PREFERRED SPECIALTY MANAGEMENT POLICY

POLICY: Multiple Sclerosis – CD20-Directed Cytolytic Antibody Infused Products Preferred Specialty Management Policy
- Briumvi® (ublituximab-xiiy intravenous infusion – TG Therapeutics)

REVIEW DATE: 11/15/2023; selected revision 03/27/2024

OVERVIEW

This Preferred Specialty Management policy involves Briumvi, a CD20-directed cytolytic antibody infused product used for **multiple sclerosis**. Briumvi is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive multiple sclerosis in adults.[1]

POLICY STATEMENT

The Multiple Sclerosis Preferred Specialty Management Program for CD20-Directed Cytolytic Antibody Infused Products has been developed to encourage the use of the Preferred Products (generic glatiramer injection, generic dimethyl fumarate delayed-release capsules, and generic fingolimod capsules). For all medications (Preferred and Non-Preferred) the patient is required to meet the respective standard *Prior Authorization Policy* criteria. The Program also directs the patient to try <u>one</u> Preferred Product prior to the approval of a Non-Preferred Product. Requests for Non-Preferred Products will also be reviewed using the exception criteria (below). All approvals are provided for 1 year. If a patient requesting a Non-Preferred Product meets the standard *Prior Authorization Policy* criteria but has not tried one Preferred Product, an offer to review for the Preferred Products will be made.

<u>Automation</u>: None.

Preferred Products:	generic glatiramer injection, OR generic dimethyl fumarate delayed-release capsules, OR generic fingolimod capsules
Non-Preferred Products:	Briumvi

RECOMMENDED EXCEPTION CRITERIA

REFERENCES

1. Briumvi® intravenous infusion [prescribing information]. Morrisville, NC: TG Therapeutics; December 2022.